UB Paderborn / Katalog / Suche / in CDI

Subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma (COLUMBA): a multicentre, open-label, non-inferiority, randomised, phase 3 trial

The Lancet. Haematology, 2020-05, Vol.7 (5), p.e370-e380

2020

Volltextzugriff (PDF)

Exposure‐Response and Population Pharmacokinetic Analyses of a Novel Subcutaneous Formulation of Daratumumab Administered to Multiple Myeloma Patients

Journal of clinical pharmacology, 2021-05, Vol.61 (5), p.614-627

2021

Volltextzugriff (PDF)

PET Study Examining Pharmacokinetics, Detection and Likeability, and Dopamine Transporter Receptor Occupancy of Short- and Long-Acting Oral Methylphenidate

The American journal of psychiatry, 2006-03, Vol.163 (3), p.387-395

2006

Volltextzugriff (PDF)

Subcutaneous daratumumab in Asian patients with heavily pretreated multiple myeloma: subgroup analyses of the noninferiority, phase 3 COLUMBA study

Annals of hematology, 2021-04, Vol.100 (4), p.1065-1077

2021

Volltextzugriff (PDF)

Daratumumab (DARA) Subcutaneous (SC) Delivery in Relapsed or Refractory Multiple Myeloma (RRMM): Population Pharmacokinetics (PPK) and Exposure-Response (E-R) Analysis

BLOOD, 2019-11, Vol.134 (Supplement_1), p.3151-3151

2019

Volltextzugriff (PDF)

Efficacy and safety of the randomized, open-label, non-inferiority, phase 3 study of subcutaneous (SC) versus intravenous (IV) daratumumab (DARA) administration in patients (pts) with relapsed or refractory multiple myeloma (RRMM): COLUMBA

JOURNAL OF CLINICAL ONCOLOGY, 2019, Vol.37 (15_suppl), p.8005-8005

2019

Volltextzugriff (PDF)

Do formulation differences alter abuse liability of methylphenidate? : A placebo-controlled, randomized, double-blind, crossover study in recreational drug users

Journal of clinical psychopharmacology, 2007-10, Vol.27 (5), p.459-467

2007

Volltextzugriff (PDF)

Phase 3, open-label, non-inferiority study of subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma: body weight subgroup analysis of Columba

BRITISH JOURNAL OF HAEMATOLOGY, 2020, Vol.189, p.22

2020

Volltextzugriff (PDF)

A human lymphocyte based ex vivo assay to study the effect of drugs on P-glycoprotein (P-gp) function

Pharmaceutical research, 2001-01, Vol.18 (1), p.39-44

2001

Volltextzugriff (PDF)

Effect of Calcineurin Inhibitor Therapy on P-gp Expression and Function in Lymphocytes of Renal Transplant Patients: A Preliminary Evaluation

Journal of clinical pharmacology, 2002-03, Vol.42 (3), p.304-311

2002

Volltextzugriff (PDF)

Stability and sorption of calcitriol in plastic tuberculin syringes

American journal of hospital pharmacy, 1992-06, Vol.49 (6), p.1463

1992

Volltextzugriff (PDF)

Menü

Weitere Dienste

Einstellungen

Subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma (COLUMBA): a multicentre, open-label, non-inferiority, randomised, phase 3 trial

Exposure‐Response and Population Pharmacokinetic Analyses of a Novel Subcutaneous Formulation of Daratumumab Administered to Multiple Myeloma Patients

PET Study Examining Pharmacokinetics, Detection and Likeability, and Dopamine Transporter Receptor Occupancy of Short- and Long-Acting Oral Methylphenidate

Subcutaneous daratumumab in Asian patients with heavily pretreated multiple myeloma: subgroup analyses of the noninferiority, phase 3 COLUMBA study

Daratumumab (DARA) Subcutaneous (SC) Delivery in Relapsed or Refractory Multiple Myeloma (RRMM): Population Pharmacokinetics (PPK) and Exposure-Response (E-R) Analysis

Randomized, Open-Label, Non-Inferiority, Phase 3 Study of Subcutaneous (SC) Versus Intravenous (IV) Daratumumab (DARA) Administration in Patients with Relapsed or Refractory Multiple Myeloma: Columba Update

Randomized, Open-Label, Non-Inferiority, Phase 3 Study of Subcutaneous (SC) Versus Intravenous (IV) Daratumumab (DARA) Administration in Patients (Pts) with Relapsed or Refractory Multiple Myeloma (RRMM): Body Weight Subgroup Analysis of Columba

Efficacy and safety of the randomized, open-label, non-inferiority, phase 3 study of subcutaneous (SC) versus intravenous (IV) daratumumab (DARA) administration in patients (pts) with relapsed or refractory multiple myeloma (RRMM): COLUMBA

Do formulation differences alter abuse liability of methylphenidate? : A placebo-controlled, randomized, double-blind, crossover study in recreational drug users

Phase 3, open-label, non-inferiority study of subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma: body weight subgroup analysis of Columba

A human lymphocyte based ex vivo assay to study the effect of drugs on P-glycoprotein (P-gp) function

Effect of Calcineurin Inhibitor Therapy on P-gp Expression and Function in Lymphocytes of Renal Transplant Patients: A Preliminary Evaluation

Stability and sorption of calcitriol in plastic tuberculin syringes

Suchergebnisse filtern